What's in a name? The evolution of the nomenclature of antipsychotic drugs.

OBJECTIVE

Psychiatry as a science and psychotherapy as an art thrive on words, words that were often coined arbitrarily and that are often used idiosyncratically. This article examines the origins, progenitors and usage of the word "antipsychotic" and explores its ramifications.

METHODS

Original publications from the 1950s onward, beginning with the report of the discovery of chlorpromazine, were sought for their specific references to the terminology of drugs used to treat psychotic disorders. Preferences for individual words, debates surrounding their adoption and changing trends in their use are reviewed from scientific, clinical and social perspectives.

RESULTS

Over the past 50 years the drugs used in the treatment of schizophrenia and other psychotic disorders have been variously labelled "tranquillizers," "neuroleptics," "ataractics," "antipsychotics" and "anti-schizophrenic agents." These terms, coined out of necessity, were quickly accepted with little debate or due consideration of their clinical, personal and social implications. The development of a new generation of antipsychotic drugs as well as the prospect of treatment strategies with diverse mechanisms of action highlight the need to re-examine the issues involved in the naming, classification and labelling of psychotropic drugs in general and of "antipsychotics" in particular.

CONCLUSION

This historical overview of the labelling of drugs used in the treatment of psychoses reflects the confusion and controversy surrounding the naming and classification of drugs and diseases in general. It also illustrates the dynamic interplay of personal beliefs, rational thinking, practical considerations and societal values in shaping the scientific process.